Rising from the Ashes of Pfizer: The Michigan Contract Research Organization Cluster

pharmacokinetic and pharmacodynamics modeling, which helps drugmakers project how a drug will be absorbed into the body, and metabolized. It also says it provides “model-based clinical trial simulations to support trial designs, program strategy and decision-making.”

Ash Stevens. This Detroit company has been around a full 45 years, developing and making active pharmaceutical ingredients for drugmakers.

Cutting Image Histology. Cutting Image, an Ann Arbor, MI company led by Wendy Rosebury-Smith and Theresa Cody, offers histology, immunohistochemistry, and histopathology services to drugmakers, biotech companies, and academic researchers.

ePharmaCMC. This South Lyon, MI-based firm has expertise in chemistry, manufacturing, and controls (CMC), which is an important part of what the FDA considers when it evaluates new drug applications.

IDSC. This Chelsea, MI-based company, whose name stands for International Discovery Services and Consulting, has a group of 20 people with an average of 28 years of pharmaceutical experience, according to its website. They do a lot of different things in the early phases of drug discovery and development. The team has a record of nominating 100 clinical candidates, 50 compounds in clinical trials, and multiple marketed drugs, according to its website.

Integrated Nonclinical Development Solutions. This Ann Arbor, MI-based company, known as INDS, was founded by a number of Pfizer veterans. It does drug discovery and development consulting. [Updated and corrected: 11:30 am, 7/7/10. An earlier version said INDS does toxicology testing, and while it consults, it doesn’t actually perform toxicology tests.]

Kalexsyn. Kalamazoo, MI-based Kalexsyn provides medicinal chemistry services to drugmakers. CEO David Zimmermann spent 23 years at Upjohn and Pharmacia before he co-founded Kalexsyn.

MPI Research. MPI, based in Mattawan, MI, offers preclinical toxicology services to drugmakers. It says it has conducted “thousands of drug safety, discovery, bioanalytical, and analytical studies.” CEO William Parfet is a former vice chairman

Author: Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.